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cells display rounded morphology, lack of pseudopodial 
activity, retarded spreading, reduced migration, and 









1D is targeted to focal adhesions and efficiently dis-












3 integrins from 
the sites of cell–matrix contact. This displacement is ob-
served on several types of extracellular matrix substrata 















1D is digitonin-insoluble and is strongly 
associated with the detergent-insoluble cytoskeleton. 




1D integrin with the actin cy-
toskeleton is consistent with and might be mediated by 
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pression in nonmuscle cells are due to its enhanced in-
teractions with both cytoskeletal and extracellular 
ligands. They parallel the transitions that muscle cells 





grin adhesive function by alternative splicing serves as a 
physiological mechanism reinforcing the cytoskeleton–





1D integrin in muscle, where extremely stable as-
sociation is required for contraction.
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 are a large family of transmembrane hetero-
dimeric receptors that play a key role in cell adhesion
to extracellular matrix (Hynes, 1992). Integrin recep-
tors serve a dual purpose, linking extracellular matrix to
the actin cytoskeleton and providing bidirectional trans-
mission of signals between the extracellular matrix and the
cytoplasm (Schwartz et al., 1995; Yamada and Miyamoto,
1995; Burridge and Chrzanowska-Wodnicka, 1996). At





are thought to interact directly with the cytoplasmic do-




 subunits, providing a link to the actin cy-
toskeleton (Horwitz et al., 1986; Otey et al., 1990; Hemler




1 is typically the most
abundant and ubiquitously expressed subunit associated




 subunits to form distinct heterodimers.
These interact with a variety of extracellular matrix and cell





1 integrin cytoplasmic domain is critical for integrin–
cytoskeleton interaction (Hayashi et al., 1990; LaFlamme
et al., 1992; Reszka et al., 1992; Ylanne et al., 1993; Lewis
and Schwartz, 1995).
Integrin functions within the cell can be regulated at dif-
ferent levels. These include cell type–specific biosynthesis
of certain integrin heterodimers, maturation and process-
ing of the receptors, as well as their transport to the cell
surface (Hynes, 1992). Another level of control of integrin
function is through regulation of the ligand-binding affin-
ity of integrins on the cell surface. This type of regulation
involves conformational changes within integrins. The con-
formational state of the extracellular domains (activation)
of integrins is regulated via their cytoplasmic tails and is
referred to as inside-out signaling (Ginsberg et al., 1992;
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O’Toole et al., 1994; Schwartz et al., 1995). Thus, deletions









 subunits can either increase or inhibit the
ligand-binding activity of integrin receptors (Takada et al.,
1992; O’Toole et al., 1994, 1995). The activation state of in-
tegrins can also be controlled by some lipid metabolites
(Hermanowski-Vosatka et al., 1992; Smyth et al., 1993) and
small GTP-binding proteins (Zhang et al., 1996; Hughes
et al., 1997). Finally, functional properties of integrin re-
ceptors can be modulated by alternative splicing involving
their cytoplasmic tails.










isoform, characteristic for all known cell types except red
blood cells and terminally differentiated striated muscles,












1C, have been characterized (Altruda et al.,
1990; Languino and Ruoslahti, 1992). Although their func-










1C can strongly inhibit cell growth
(Balzac et al., 1993, 1994; Meredith et al., 1995). The alter-








1C have no homo-




1A isoform and are unable to localize
to cell–matrix adhesion sites apparently because of im-
paired interaction with the actin cytoskeleton (Balzac et al.,


















1D, is highly conserved at least through-
out vertebrate evolution, suggesting an important role for
this muscle-specific variant (van der Flier et al., 1995; Zhid-




1 integrin is localized at junctional structures of stri-










taining heterodimers is essential for myodifferentiation
and the formation of sarcomeric cytoarchitecture (Menko
and Boettiger, 1987; Volk et al., 1990). Integrin-mediated
cytoskeleton-matrix linkage has to be distinct in muscle cells
because of high tensile forces transmitted across the mem-
brane and enhanced stability of muscle adhesive struc-



















1A integrin in differentiated
striated muscles (Belkin et al., 1996). Its cytoplasmic do-





servation of both NPXY motifs involved in the regulation
of ligand-binding affinity (Tamkun et al., 1986; Argraves





1D accumulates at all major cell–matrix adhesion








1D is a predominant integrin in adult skeletal and

















veloping heart muscle (Brancaccio et al., 1997). The data





plays a crucial role in linking the subsarcolemmal cytoskel-
eton to the surrounding extracellular matrix in muscle tis-
sues (Belkin et al., 1996; Fassler et al., 1996).











1 integrin is able to interact with the nonmuscle
cytoskeleton as well (Belkin et al., 1996). To get an insight









1A cytoplasmic domain iso-
forms in CHO cells and the mouse GD25 cell line. GD25




1 integrin as a consequence of gene
inactivation (Wennerberg et al., 1996). Here we report that




1D integrin in nonmuscle cells leads to
a conversion of cellular phenotype. The observed alter-
ations in cell morphology, inhibition of spreading and mo-
tility, as well as an increase in the ligand-binding affinity,
fibronectin matrix assembly and contractility, are caused




1D integrin with both the





mediated enhancement of actin–membrane attachment is,
at least in part, due to a higher affinity interaction of this
integrin with the focal adhesion protein, talin. The altered




1D cytoplasmic domain causes a confor-
mational change of its ectodomain via inside-out signaling
mechanisms, leading to activation of ligand binding. Rein-





reflects a key role for this integrin as a cytoskeleton–matrix










1 integrin were used in this study: TS2/









taining heterodimers was a gift from Dr. M. Hemler (Dana-Farber Cancer
Institute, Boston, MA) (Hemler et al., 1984; Arroyo et al., 1992); function-




1 integrin (Carter et al., 1990) was





integrin (Ylanne and Virtanen, 1989); 12G10 mAb, which reacts with acti-




























1 integrin subunit (Bazzoni et al., 1995);




1 integrin (Hemler et al., 1984), conjugated









1 integrin and inhibitory








1 heterodimer were generous gifts
from Dr. R. Juliano (University of North Carolina, Chapel Hill, NC)














v H9.2B8 mAb (Moulder et al., 1991) was ob-













5 cytoplasmic domains were described earlier (Defil-
ippi et al., 1992; Balzac et al., 1994). mAb 8d4 against talin was obtained





was from Chemicon International, Inc. (Temecula, CA). Rabbit polyclonal
antibody against platelet myosin II, cross-reacting with nonmuscle myo-
sin, was a gift from Dr. R. Adelstein (National Institutes of Health, Be-
thesda, MD). Rabbit polyclonal antibody against human plasma fibronec-
tin (Fn) was provided by Dr. L.B. Chen (Dana-Farber Cancer Institute).
Human plasma Fn was from GIBCO BRL. Recombinant, 12-kD cell-
binding Fn fragment corresponded to the tenth Arg-Gly-Asp–containing
(cell-binding), type III Fn repeat. Cytochalasin D was from Sigma Chemi-
cal Co.. Digitonin was purchased from Sigma Chemical Co. and purified





bel and methionine- and cysteine-free medium were from ICN Biomedi-











Expression Constructs, Transfection, and Cell Culture
 









SV40-based expression vector pECE (Ellis et al., 1986), were transfected




1-minus GD25 cell line (Wennerberg et al., 1996), and
 








transfectants were selected as described (Belkin et al., 1996). More than




1 integrin; the expres-








1D integrins were very similar and




1 integrin subunit in
CHO cells and close to the levels of the endogenous av and b3 integrins in
GD25 transfectants. CHO transfectants were cultured in Ham’s F12 me-
dium with 10% FBS, and GD25 transfectants were cultured in DME plus
10% FBS.
Morphological Analysis and Spreading
For analysis of cell phenotype, CHO transfectants were plated and cul-
tured for 1 d on Fn-coated dishes. Phase-contrast photographs of live
b1A-CHO and b1D-CHO cells were taken on an inverted microscope.
The outlines of randomly chosen cells not in contact with other cells were
analyzed by the computer Tracer V1.0 software (Dunn and Brown, 1986).
The spread area, cell perimeter, and two morphometric parameters of cell
shape, cell dispersion and elongation, were calculated as characteristics of
cell spreading and polarization. For analysis of the time course of spread-
ing, b1A- and b1D-transfected CHO and GD25 cells were plated in se-
rum-free medium on Fn, laminin, vitronectin, or on immobilized mAb
TS2/16 to human b1 integrin (Balzac et al., 1994; Belkin et al., 1996). After
specific periods of time, cells were fixed with formaldehyde, stained with
Coomassie brilliant blue (Balzac et al., 1994), and then photographed.
Measurements of the Ligand-Binding Affinity
The binding of the 125I-labeled Fn(III)10 fragment to b1A-CHO, b1D-
CHO, b1A-GD25, and b1D-GD25 cells in suspension was quantified as
described (O’Toole et al., 1990; Wu et al., 1995). Since CHO cells express
the endogenous a5b1, and b1-minus GD25 cells express avb3 as a major
Fn-binding integrin (Wennerberg et al., 1996), inhibitory mAbs PB1
against hamster a5b1 or H9.2B8 against mouse av were used for CHO
and GD25 cells, respectively. In some experiments, blocking P4C10 mAb
against human b1 integrin was used in combination with either PB1 mAb
(for CHO cells) or H9.2B8 mAb (for GD25 cells). Cells (0.2 ml of 5 3 106
cells/ml) in Tyrode’s buffer were incubated with specified concentrations
of 125I-labeled Fn(III)10 fragment (sp act 0.12 mCi/nM) for 30 min at 378C
either alone or in the presence of 10 mg/ml of purified TS2/16 mAb, which
activates human b1 integrins. Coincubation with an excess of unlabeled
Fn(III)10 fragment (0.5 mg/ml) was used to determine and subtract the
nonspecific background binding. 50-ml aliquots were layered on 0.3 ml of
20% sucrose in Tyrode’s buffer and centrifuged for 3 min at 12,000 rpm.
Radioactivity associated with the cell pellet was determined in a gamma
counter.
Flow Cytometry
Cell surface expression of the transfected human b1A or b1D integrins in
CHO and GD25 transfectants was assessed with 102DF5 and TS2/16 mAbs,
whose binding to the b1 subunit is conformation independent. Their ex-
pression levels were compared to those of the endogenous hamster b1 in-
tegrin (examined with 7E2 mAb). 12G10 mAb reacting with activated hu-
man b1 integrin subunit (Mould et al., 1995) and conformation-specific
9EG7 anti–human b1 mAb (Bazzoni et al., 1995) were used either in the
absence of Mn21 ions or in the presence of 1 mM Mn21. Fluorescein-
labeled, affinity-purified donkey anti–mouse IgG (Chemicon International,
Inc.) was used as secondary antibody.
Fn Matrix Assembly Assays
b1A-CHO, b1D-CHO, as well as b1A-GD25 and b1D-GD25 cells did not
assemble Fn matrix well when confluent cell monolayers were cultured in
growth medium containing 1% FBS for 2 d. To boost the formation of Fn
matrix, exogenous human plasma Fn was added at 200 nM concentration
for 2 d to the confluent cell monolayers grown on glass coverslips. Inhibi-
tory mAbs PB1 against hamster a5b1 and H9.2B8 against mouse av were
used to block Fn matrix assembly by the endogenous Fn-binding integrins
in CHO and GD25 cells, respectively. Activating TS2/16 and inhibitory
P4C10 mAbs were used for the transfected human b1A and b1D inte-
grins. After 2 d, cell monolayers were fixed and stained with anti-Fn anti-
body. Stained cells were observed using a Zeiss epifluorescence micro-
scope (Carl Zeiss Inc., Thornwood, NY) and representative fields were
photographed using equal exposure lengths on Kodak T-Max 400 film
(Eastman Kodak, Rochester, NY).
To quantitate Fn incorporation into deoxycholate-insoluble matrix, con-
fluent b1A-CHO, b1D-CHO, b1A-GD25, and b1D-GD25 cultures were
incubated for 2 d with 100, 200, or 300 nM of 125I-labeled Fn (sp act 0.08
mCi/nM) in growth medium containing 1% FBS and blocking and activat-
ing mAbs as specified above. Deoxycholate-insoluble fraction was ob-
tained from cell monolayers as described (McKeown-Longo and Mosher,
1985; Wu et al., 1993, 1995).125I-labeled Fn incorporated into the deoxy-
cholate-insoluble extracellular matrix was analyzed by reducing SDS-
PAGE (6% running gel) and autoradiography. Iodinated Fn bands were
cut out and counted in a gamma counter.
Migration Assays
Migratory properties of b1A-CHO, b1D-CHO, b1A-GD25, and b1D-
GD25 cells were examined by a wound closure assay and time lapse
videomicroscopy. For the wound closure assay, confluent cell monolayers
grown on Fn-coated coverslips were wounded by dragging a sterile 1-mm
pipette tip across the monolayer to create cell-free fields (Romer et al.,
1994). 2 d later, glass coverslips were fixed with formaldehyde, stained
with Coomassie blue, and then photographed.
For time lapse videomicroscopy, b1A- and b1D-transfected CHO and
GD25 cells were plated on plastic dishes coated with 10 mg/ml of human
plasma Fn. Five to six cells were scanned per field in eight different fields,
every 20 min for 4 h. The displacement of the cell center as a function of
time was calculated for each cell using nonoverlapping time intervals. To
block the endogenous Fn receptors, PB1 mAb was used for CHO trans-
fectants and H9.2B8 mAb for GD25 transfectants. TS2/16 was used as the
activating mAb and P4C10 as the blocking mAb for the transfected hu-
man b1A and b1D integrins.
Analysis of the Association of b1A and b1D Integrins 
with a Subunits
b1D-CHO cells as well as b1A- and b1D-GD25 transfectants were lysed
in buffer containing 1% Triton X-100 in 50 mM TrisCl, 150 mM NaCl, pH
7.5, and protease inhibitors. Each lysate was clarified by centrifugation, di-
vided into four equal parts, and the transfected human b1 integrins were
immunoprecipitated using TS2/16 mAb, whereas a3, a5, and av subunits
were immunoprecipitated with antibodies against cytoplasmic domains of
these integrins. The resulting immunoprecipitates were run on 10% gel
and blots were probed with the isoform-specific antibodies against b1A or
b1D integrins.
Localization of the Transfected b1A and b1D Integrins 
and the Endogenous b1A and av Subunits and Analysis 
of their Association with the Actin Cytoskeleton
To localize the transfected and the endogenous b1 integrins, as well as the
endogenous av integrins in the transfectants, cells cultured on Fn-coated
coverslips were fixed with formaldehyde and permeabilized with 0.5%
Triton X-100 in PBS. CHO transfectants were costained with fluorescein-
labeled A1A5 mAb to human b1 and rhodamine-labeled 7E2 mAb to
hamster b1 integrin. GD25 cells were double stained with mouse fluores-
cein–labeled A1A5 mAb and rabbit anti-av antibody followed by
rhodamine-labeled donkey anti–rabbit antibody (Chemicon International
Inc.). Stained cells were observed using epifluorescence with a Zeiss Axio-
phot microscope and photographed using Kodak T-Max 400 film.
To study whether the solubility of integrins in digitonin correlates with
their cytoskeletal association, 35S-labeled b1A-CHO and b1D-CHO cells,
either untreated or treated for 1 h with 10 mM of cytochalasin D, were
fractionated into soluble and cytoskeleton-associated fractions by sequen-
tial extraction at 48C with 0.1% digitonin in 50 mM Pipes, 1 mM MgCl2,
1 mM EGTA, 1 mM EDTA, pH 6.9, and then with radioimmunoprecipita-
tion assay (RIPA) buffer (50 mM TrisCl, 150 mM NaCl, 1% Triton X-100,
0.5% Na-deoxycholate, and 0.1% SDS, pH 7.5). Both buffers contained 10
mg/ml leupeptin, 10 mg/ml pepstatin, and 0.5 mM PMSF as protease inhib-
itors. The transfected b1A and b1D integrins were immunoprecipitated from
digitonin- and RIPA-soluble fractions using TS2/16 mAb. 35S-labeled b1
immunoprecipitates were run on 10% gels and analyzed by autoradiography.
To assess the association of the transfected and the endogenous b1 in-
tegrin subunits and the endogenous av integrins with the actin cytoskele-
ton, 35S-labeled CHO and GD25 transfectants were sequentially extracted
with digitonin and RIPA buffers as described above. Immunoprecipita-
tion of the transfected human b1A and b1D integrins from both cellular
fractions was performed with TS2/16 mAb. 7E2 mAb antibody was used
for the endogenous hamster b1A integrin. Rabbit anti-av antibody was
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used to immunoprecipitate the endogenous avb3/avb5 integrins from
GD25 transfectants. 35S-labeled b1 and av immunoprecipitates were ana-
lyzed by SDS-PAGE on 10% gels and subsequent autoradiography.
Analysis of the Association of b1A and b1D Integrins 
with Talin and a-Actinin by Coimmunoprecipitation
To compare the association of b1A and b1D integrins with talin and
a-actinin, 5 3 106 transfected cells were incubated in suspension with 10
mg of either purified TS2/16 mAb, 12G10 mAb, or 7E2 mAb at 48C for 30
min on a rotator. In the case of 12G10 mAb, cells were either preincu-
bated for 5 min with 1 mM Mn21 or used in the absence of Mn21. Cells
were centrifuged (1,000 rpm, 3 min) and the pellets were extracted for 3
min on ice with buffer containing 0.5% digitonin in 50 mM Pipes, 1 mM
MgCl2, 1 mM EGTA, 1 mM EDTA, pH 6.9, with 10 mg/ml leupeptin, 10
mg/ml pepstatin, and 0.5 mM PMSF. Under these conditions z80–90% of
cellular b1 integrins was extracted. Cell extracts were centrifuged (12,000
rpm, 30 min, 48C) and the resulting supernatants incubated at 48C for 45
min with donkey anti–mouse IgG immobilized on protein A–Sepharose
beads. Immunoprecipitates were washed with the same buffer, boiled in
SDS sample buffer, and then run on 10% gels. Proteins were transferred
onto Immobilon membranes (Millipore Corp., Bedford, MA) and blotted
with either rabbit polyclonal antibody to human b1 integrin, 8d4 mAb
against talin, or 1682 mAb against a-actinin. To verify the equal amount
of b1A and b1D isoforms in the immunoprecipitates, the blots were
stripped and reprobed with the isoform-specific antibodies against b1A
and b1D (Belkin et al., 1996).
Interaction of Talin and a-Actinin with b1A and b1D 
Cytoplasmic Domain Peptides
Talin was purified from human platelets as described earlier (Collier and
Wang, 1982). a-Actinin purification from chicken gizzards was performed
as described (Otey et al., 1990). Talin and a-actinin were iodinated using
125I and Iodobeads (Pierce Chemical Co., Rockford, IL). The proteins
were labeled to a specific activity of 1.2 3 106 cpm/mg for talin and 7.5 3
106 cpm/mg for a-actinin.
Full-length cytoplasmic domain peptides of b1A and b1D integrins (Bel-
kin et al., 1996) were iodinated using Iodogen method. Both peptides
were initially tested for their binding to the microtiter wells in the range of
1–150 mM concentrations in buffer containing 50 mM TrisCl, 150 mM
NaCl, pH 7.5. Since they bound similarly to the wells, saturating 50 mM
concentration of b1A and b1D peptides was used in subsequent experi-
ments to immobilize them on plastic 96-well microtiter plates for 1 h at
378C. After blocking with 2% BSA in 50 mM TrisCl, 150 mM NaCl, wells
with the bound peptides were incubated with 1 nM of 125I-talin or 125I–
a-actinin and 1 nM to 1 mM concentrations of unlabeled talin or a-actinin
in the same buffer with 0.1% BSA for 4 h at 378C. After the incubations,
wells were washed three times with the same buffer and bound radioactiv-
ity was measured in a gamma counter. Nonspecific background was deter-
mined and subtracted for talin and a-actinin binding to BSA-coated wells.
Measurements of Cellular Contractility and Myosin 
Light Chain Phosphorylation
Silicone rubber substrata for assessing cellular contractility were made as
described previously (Harris et al., 1980; Danowski, 1989). The UV glow
discharge polymerization was used in combination with gold-palladium
coating (Chrzanowska-Wodnicka and Burridge, 1996). 5- and 12-s poly-
merization was used for CHO and GD25 transfectants, respectively. Cells
were plated on the cross-linked rubber substrata in growth medium with
10% FBS and photographed on the next day.
Possible changes in myosin light chain phosphorylation were examined
as described (Chrzanowska-Wodnicka and Burridge, 1996). Briefly, sub-
confluent b1A-CHO and b1D-CHO cells cultured on Fn-coated, 35-mm
dishes, were labeled for 4 h with 20 mCi/ml of 35S-Translabel and 100 mCi/ml
of [32P]orthophosphate in phosphate-free medium. Cells were washed
with PBS and equal amounts of material, as judged by 35S-incorporated
radioactivity, were taken for immunoprecipitation with antimyosin anti-
body, followed by protein A–Sepharose beads. Immunoprecipitates were
washed, boiled in SDS sample buffer, and then run on 15% polyacryla-
mide gel. Phosphorylated myosin light chain bands were visualized by au-
toradiography using three sheets of aluminum foil to block traces of 35S ra-
diation.
Results
b1D Integrin Alters Cell Morphology and
Inhibits Spreading
The levels of surface expression of the transfected human
b1A and b1D, measured with mAbs 102DF5 and TS2/16,
were very close to each other in both CHO and GD25
transfectants (Table I). They were also similar to the levels
of the endogenous b1A in CHO transfectants and av inte-
grins in GD25 cells (see Fig. 9, I and J). No difference in
association of the transfected b1A and b1D with endoge-
nous a subunits was found in the two types of transfectants
(Fig. 7).
To determine possible effects of b1A and b1D integrin
expression on cell morphology, CHO transfectants were
grown on Fn for 1 d (Fig. 1, A and B). b1D-CHO cells ap-
pear more rounded with fewer cytoplasmic extensions at
their periphery than their b1A-transfected counterparts.
Statistical analysis of the cell shape was performed for ran-
domly chosen b1A-CHO and b1D-CHO cells (Dunn and
Brown, 1986). This demonstrated that spread areas were
similar for b1A and b1D transfectants, but the average cell
perimeter was z20% lower for b1D-CHO cells (Table II).
Two cell shape parameters, dispersion and elongation, rep-
resenting measures of cell multipolarity and bipolarity, re-
spectively, were significantly lower for b1D transfectants.
These data indicated that pseudopodial activity and cell
polarization were reduced in CHO cells expressing b1D
integrin.
To analyze the time course of spreading, b1A and b1D
transfectants were plated on purified Fn (Fig. 1, C–F).
Spreading of CHO cells expressing b1D integrin on Fn
was significantly delayed compared with b1A transfectants.
When both b1A and b1D transfectants were plated on
TS2/16 mAb specific for human b1 integrin, b1D-CHO
were less spread than b1A-CHO cells (Fig. 1, G and H).
Notably, b1D transfectants also spread more slowly on
laminin, vitronectin, and 7E2 mAb against hamster b1 in-
tegrin (data not shown), indicating that inhibition of spread-
ing was not limited to a certain type of substrate. Likewise,
spreading of b1D-GD25 cells on both Fn and vitronectin
was significantly delayed compared with the spreading of
Table I. Expression Levels and Activation States of
Transfected Human b1A and b1D Integrins in CHO and
GD25 Transfectants
mAb 12G10
Cell type mAb 102DF5* mAb 12G10*
mAb 12G10 1 
1mM Mn21*
mAb 12G10 1 
1 mM Mn 21‡
b1A-CHO 43.1 9.2 33.6 27.4
b1D-CHO 34.4 21.8 28.2 77.3
b1A-GD25 42.2 12.2 32.4 37.7
b1D-GD25 38.9 29.1 36.7 79.3
mAb 9EG7 
mAb TS2/16* mAb 9EG7*
mAb 9EG7 1 
1mM Mn21*
mAb 9EG7 1
1 mM Mn 21‡
b1A-GD25 105 39 89 43.8
b1D-GD25 95 69 78 88.4
*Values are mean fluorescence intensities from a representative experiment.
‡Values are percentages.
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b1A-GD25 cells (Fig. 1, I–L). These observations sug-
gested that retardation of spreading was a general phe-
nomenon of b1D expression.
Constitutive Activation of the b1D Integrin 
Ectodomain Increases Ligand Binding
To characterize the affinity states of b1A and b1D integrins,
the binding of the Fn(III)10 fragment to b1A- and b1D-
transfected CHO and GD25 cells in suspension was exam-
ined. In the presence of function-blocking mAbs PB1 and
H9.2B8, which inhibited endogenous Fn-binding hamster
a5b1 and mouse avb3 integrins, respectively, b1D trans-
fectants exhibited a significant increase in binding the sol-
uble ligand compared with b1A-expressing cells (Fig. 2, A
and B). TS2/16 mAb, which activates human b1 integrin,
markedly increased Fn(III)10 fragment binding to both
b1A-CHO and b1A-GD25 cells, whereas the ligand bind-
ing by b1D transfectants in the presence of TS2/16 mAb
remained unaffected (Fig. 2, A and B). Blocking P4C10
mAb against human b1 integrin completely abolished the
binding of Fn(III)10 fragment to all types of transfectants
(Fig. 2, A and B), therefore proving its specificity.
To further assess the difference in the conformation of
the ectodomains of the transfected b1A and b1D, a flow
cytometry analysis was used with mAb 12G10. This anti-
body recognizes preferentially a Mn21- and ligand-induced
conformation of the human b1 integrin subunit (Mould
et al., 1995; Mould, 1996). The amount of 12G10 mAb
bound to the cell surface was significantly higher for b1D-
expressing CHO and GD25 cells, than for b1A-expressing
cells. Moreover, the binding of 12G10 mAb was almost un-
changed for b1D-CHO and b1D-GD25 cells in the pres-
ence of Mn21, whereas the 12G10 mAb binding to both
types of b1A transfectants was dramatically increased by
Mn21 (Table I). Another mAb, 9EG7, whose binding to
human b1 integrin is stimulated by ligands and Mn21, but
inhibited by Ca21 (Bazzoni et al., 1995), also reacted more
strongly with b1D-GD25 compared with b1A-GD25 cells
(Table I). Together, these results showed that in b1D-
expressing cells in suspension the majority (z77–88%) of
b1D integrins were constitutively activated on the cell sur-
face, whereas only z27–44% of the transfected b1A inte-
grins were present in the activated state.
b1D Enhances Fn Matrix Assembly
Fn biosynthesis and secretion levels in CHO and GD25
cells were not altered by b1A or b1D expression and ap-
peared to be identical for each pair of transfectants (data
not shown). Fn matrix assembly by b1A- and b1D-trans-
fected cells was analyzed with the exogenous Fn by both
immunofluorescence and measurements of 125I-Fn incor-
poration into deoxycholate-insoluble matrix (McKeown-
Longo and Mosher, 1985; Wu et al., 1993, 1995). Using dif-
ferent concentrations of the exogenous Fn, we consistently
observed an enhanced Fn matrix assembly by b1D trans-
fectants compared to their b1A-expressing counterparts
(Fig. 3 A). In our subsequent experiments we used 200 nM
of exogenous Fn for matrix assembly studies with the
transfectants. There was no difference in Fn matrix assem-
bly between b1A and b1D transfectants in the presence of
blocking P4C10 mAb against human b1 integrin, showing
that the observed effects can be ascribed specifically to the
expressed b1D (Fig. 3 B).
In the presence of blocking anti–hamster a5b1 integrin
mAb PB1 (for CHO cells) or inhibitory anti–mouse av in-
tegrin mAb H9.2B8 (for GD25 cells), b1D transfectants
assembled more abundant meshwork of Fn fibrils, than
b1A-expressing counterparts (Fig. 4, A, B, E, F, and I, a, b,
e, and f). Activating mAb TS2/16 significantly increased
Fn matrix assembly by b1A-CHO and b1A-GD25 cells,
but did not change the levels of assembly for b1D-trans-
fected CHO and GD25 cells (Fig. 4, C, D, G, H, and I, c, d,
g, and h). Quantitation of 125I-Fn incorporated into the ex-
tracellular matrix showed a five- to sixfold increase in Fn
assembly by b1D compared with b1A integrin in CHO
and GD25 cells (Fig. 4, I and J). Interestingly, whereas
mAb TS2/16 caused two- to threefold increase in Fn ma-
trix assembly by b1A integrin for both types of transfec-
tants, these levels appeared still much lower than those ex-
hibited by b1D integrin (Fig. 4, I and J).
Figure 1. Altered morphology and inhibited spreading of CHO
and GD25 cells expressing b1D integrin. b1A-CHO (A) and
b1D-CHO (B) cells were plated on Fn and cultured for 1 d. b1A-
CHO (C, E, and G) and b1D-CHO (D, F, and H) cells were
plated in serum-free medium on Fn for 30 min (C and D), or 1 h
(E and F); or on TS2/16 mAb against human b1 integrin for 2 h
(G and H). b1A-GD25 (I and K) and b1D-GD25 (J and L) cells
were plated in serum-free medium on Fn (I and J) or vitronectin
(K and L) for 1 h. Cells were fixed with formaldehyde and
stained with Coomassie blue. Bar, 50 mm.
Table II. Cell Shape Parameters of b1A-CHO and b1D-CHO 
Cells
Cell type Area, mm2‡ Perimeter, mm‡ Dispersion‡ Elongation‡
b1A-CHO* 814 6 37 147 6 4 0.237 6 0.016 1.059 6 0.065
b1D-CHO* 742 6 34 118 6 3 0.112 6 0.009 0.769 6 0.045
*107 cells were analyzed for b1A-CHO population and 109 cells for b1D-CHO pop-
ulation.
‡Given are means and SE.
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1D-expressing cells was also ex-
amined on Fn by time lapse videomicroscopy in the presence
of blocking mAbs PB1 for CHO and H9.2B8 for GD25
transfectants (Fig. 6). In both cases when the endogenous
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test whether integrin insolubility in digitonin is deter-
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1 integrins in digitonin depends on their association with
the actin cytoskeleton.
Figure 3. b1D integrin en-
hances Fn matrix assembly.
(A and B) Incorporation of
exogenous Fn into deoxycho-
late-insoluble matrix by b1A-
and b1D-transfected CHO
and GD25 cells. 125I-Labeled
deoxycholate-insoluble Fn
was visualized by SDS elec-
trophoresis on 6% gels under
reducing conditions, after au-
toradiography. 125I-Fn bands
were cut out and radioactiv-
ity was counted in a gamma
counter. Bars represent the
means of triplicate determi-
nations. (A) Cells were cul-
tured for 2 d with 100, 200, or
300 nM of exogenous Fn. (B)
Cells were cultured for 2 d
with 200 nM of exogenous Fn
in the absence or in the pres-
ence of function-blocking
P4C10 mAb against the
transfected human b1 inte-
grins.
Figure 2. Increased ligand binding by b1D inte-
grin. Ligand-binding properties of b1A- and
b1D-transfected CHO (A) and GD25 (B) cells.
Binding of 125I-labeled Fn(III)10 fragment to b1A
(open marks) and b1D (filled marks) transfec-
tants either in the absence (squares) or presence
of the activating anti–human b1 integrin TS2/16
mAb (triangles), or the function-blocking anti–
human b1 integrin P4C10 mAb (circles) was de-
termined as described in the Materials and Meth-
ods. The endogenous Fn-binding hamster a5b1
and mouse avb3 integrins were blocked by prein-
cubation of the CHO and GD25 cells with the in-
hibitory PB1 and H9.2B8 mAbs, respectively.
Note that b1A-transfected, but not b1D-trans-
fected CHO and GD25 cells, display a significant
increase in Fn(III)10 fragment binding in the
presence of activating TS2/16 mAb. Depicted are
the means from triplicate measurements.
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b1D Integrin Displaces the Endogenous b1A and av 
Subunits from Focal Adhesions and Associates Strongly 
with the Digitonin-insoluble Cytoskeleton
Since b1D and b1A integrins have structurally different
cytoplasmic domains, and the two types of transfectants
displayed dissimilar phenotypes, we next attempted to
compare cytoskeletal interactions of the b1A and b1D iso-
forms. To localize the transfected and the endogenous b1
integrins in CHO transfectants, cells grown on Fn were
double stained with anti–human b1 and anti–hamster b1
mAbs. In b1A-CHO cells, both the transfected and the en-
dogenous b1A subunits colocalized at focal adhesions
(Fig. 9, A and C). b1D integrin was prominently localized
at focal adhesions of b1D-CHO cells. Surprisingly, no en-
dogenous b1A integrin was detected in focal adhesions of
b1D transfectants grown on Fn or other extracellular ma-
trix proteins (Fig. 9, B and D; and data not shown). Simi-
larly, both the transfected b1A and b1D integrins were
targeted to focal adhesions of GD25 transfectants on Fn
(Fig. 9, E and F). The endogenous av subunit of Fn-bind-
ing avb3 integrin in b1A-GD25 cells was at least partially
colocalized with b1A at sites of cell–matrix contact (av
does not pair with b1 integrins in GD25 cells; Wennerberg
et al., 1996). In contrast, b1D displaced the endogenous av
integrins from focal adhesions (Fig. 9, G and H). There-
fore, the displacement of b1A and av integrins from focal
adhesions by expressed b1D was a general phenomenon,
suggesting a considerably stronger association of b1D in-
tegrin with the actin cytoskeleton.
To define biochemically the modes of b1A and b1D in-
teraction with the cytoskeleton, both the transfected b1A
and b1D, as well as the endogenous b1A and av integrins
were immunoprecipitated from soluble and cytoskeleton-
associated fractions of 35S-labeled transfectants grown on
Fn (Fig. 9, I and J). In b1A-CHO cells, the transfected
b1A was equally distributed between the soluble and the
cytoskeletal fractions, wheras the majority of the endoge-
nous hamster b1A subunit was associated with the cyto-
skeleton. In contrast, b1D was found exclusively in the cy-
toskeletal fraction, whereas almost all the endogenous
b1A integrin was present in the soluble fraction of b1D-
CHO cells, displaced from the cytoskeleton (Fig. 9 I). Cy-
toskeletal associations of the transfected b1A and b1D
integrins in GD25 transfectants were similar to those ob-
served in CHO transfectants. Again, much of the trans-
fected b1A integrin was digitonin soluble. However, the
majority of b1D integrin was digitonin insoluble, whereas
most of the endogenous avb3/avb5 integrins were dis-
Figure 4. Activation of b1D integrin extracellular domain contributes to the increased b1D-mediated assembly of Fn matrix. (A–H) Im-
munofluorescent detection of Fn matrix deposition. Confluent monolayers of b1A-CHO (A and C), b1D-CHO (B and D), b1A-GD25
(E and G), and b1D-GD25 (F and H) cells were cultured for 2 d with 200 nM of exogenous human plasma Fn either in the absence (A,
B, E, and F) or presence (C, D, G, and H) of activating anti–human b1 TS2/16 mAb. Inhibitory PB1 (A–D) and H9.2B8 (E–H) mAbs
were used in the growth media to block the endogenous Fn-binding a5b1 and avb3 integrins, respectively. Note that more abundant Fn
matrix was assembled by b1D-transfected cells (B, D, F, and H). A significant increase in Fn matrix assembly occurred when b1A-trans-
fected cells (C and G), but not b1D-transfected cells (D and H) were incubated in the presence of TS2/16 mAb. Bar, 200 mm. (I and J)
Biochemical evaluation of Fn matrix assembly. Cells were cultured for 2 d with 200 nM of exogenous Fn. (I) 125I-Labeled Fn was visual-
ized by SDS-PAGE and autoradiography after it had been incorporated into deoxycholate-insoluble matrix of b1A-CHO (a and c),
b1D-CHO (b and d), b1A-GD25 (e and g) and b1D-GD25 (f and h) cells either in the absence (I: a, b, e, and f; J, dark bars) or in the
presence (I: c, d, g, and h; J, hatched bars) of activating TS2/16 mAb. mAbs PB1 (a–d) and H9.2B8 (e–h) were used as blocking antibod-
ies for the endogenous Fn-binding integrins. 125I-Fn was used as a marker for SDS-PAGE (i). Molecular weight markers (from top to
bottom) are 200, 116, 97, and 68 kD. They are indicated to the left of the gel. (J) 125I-Fn bands for b1A and b1D transfectants from the
experiments shown in I were cut out and quantitated in a gamma counter. Bars in J represent the means of triplicate measurements for
two independent experiments.
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placed from their association with the cytoskeleton by the
transfected b1D (Fig. 9 J).
Differential Interaction of b1A and b1D Integrins with 
Talin and a-Actinin
At least two cytoskeletal proteins, talin and a-actinin, are
known to interact in vitro with the cytoplasmic domain of
b1A integrin (Horwitz et al., 1986; Otey et al., 1990). To
identify cytoskeletal proteins, associated preferentially
with the b1D integrin subunit in vivo, antibody clustering
of the transfected b1A and b1D integrins on the surface of
CHO and GD25 transfectants was used in combination
with subsequent immunoprecipitation and analysis of the
immunoprecipitates (Miyamoto et al., 1995). Several cy-
toskeletal proteins, including actin, talin, a-actinin, and
vinculin coprecipitated with the transfected b1 integrins
(data not shown). When b1A and b1D immunoprecipi-
tates, obtained with activating TS2/16 anti–human b1 mAb,
were compared by immunoblotting with mAb 8d4 against
talin, a significantly stronger talin band was detected in as-
sociation with b1D integrin in both CHO and GD25 trans-
fectants (Fig. 10, A, a, a9, b, and b9; and D, a, a9, b, and b9).
This preferential association of talin with b1D compared
with b1A integrin did not depend on the nature of anti-b1
mAb used for clustering. 12G10 mAb, which recognizes a
Mn21- and ligand-induced conformation of human b1 inte-
grin, precipitated more talin from b1D-CHO than from
b1A-CHO cells both in the absence or in the presence of 1
mM Mn21 (Fig. 10, A, c, c9, d, and d9). In control immuno-
precipitations with the 7E2 mAb against the endogenous
hamster b1 integrin, equal amounts of talin were detected
in association with the endogenous b1A in CHO transfec-
tants (Fig. 10, A, e, and e9). Interestingly, when anti–human
b1 integrin immunoprecipitates from both types of trans-
fectants were probed for a-actinin, more a-actinin was de-
tected in association with b1A than with b1D integrin
(Fig. 10, A, f, and f9; and D, c, and c9). To ensure equal
amounts of these isoforms in the immunoprecipitates, all
the samples used in these experiments were also examined
Figure 5. Expression of b1D integrin reduces migration. (A–D)
Wounding assays. Confluent monolayers of b1A-CHO (A), b1D-
CHO (B), b1A-GD25 (C), and b1D-GD25 (D) cells were scraped
to generate 1-mm-wide wounds. After 2 d, cells were fixed,
stained and then photographed. The direction of cell migration is
shown to the left of the micrographs. (E) Time lapse videomi-
croscopy analysis of migratory behavior of b1A- and b1D-trans-
fected CHO and GD25 cells. Either untreated cells (light bars),
or cells in the presence of blocking P4C10 mAb against human b1
integrin (dark bars) were observed. Bar, 200 mm.
Figure 6. The role of activa-
tion of the b1D ectodomain
in the decreased migration of
b1D transfectants. Cell mi-
gration of b1A and b1D
transfectants on Fn was ana-
lyzed by time lapse videomi-
croscopy. Inhibitory mAbs
PB1 and H9.2B8 were used
to block the endogenous Fn-
binding a5b1 integrin in
CHO and avb3 integrin in
GD25 transfectants. The ex-
periments were performed in the absence (dark bars) or presence
(hatched bars) of activating TS2/16 mAb.
Figure 7. Association of b1A
and b1D integrins with a
subunits in CHO and GD25
transfectants. Immunopre-
cipitates containing the
transfected human b1 inte-
grin subunit (1), a3 subunit
(2), a5 subunit (3), or av sub-
unit (4) from b1D-CHO (A
and B), b1A-GD25 (C and
D), and b1D-GD25 (E and
F) cells were run on 10% gel and subjected to immunoblotting
with the isoform-specific antibodies against b1A (A, C, and E)
and b1D (B, D, and F) integrins.
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with the isoform-specific antibodies against b1A (Fig. 10,
B and E) and b1D (Fig. 10, C and F) integrins (Belkin et
al., 1996). Besides the immunoprecipitates from b1A-
CHO and b1D-CHO cells with the conformation-specific
mAb 12G10 in the absence of Mn21 (Fig. 10, B, c; and C,
c9), all other samples contained equal amounts of b1 inte-
grins (Fig. 10, B, C, E, and F).
To compare further the interactions of b1A and b1D in-
tegrins with talin and a-actinin, in vitro solid phase binding
assays were performed with 125I-talin, 125I–a-actinin, and
immobilized full-length synthetic peptides, corresponding
to the b1A and b1D cytoplasmic domains (Fig. 11). First,
we tested the binding of 125I-labeled b1A and b1D cyto-
plasmic domain peptides to the microtiter wells (Fig. 11 A).
The amounts of the b1A and b1D peptides adsorbed to
the wells were almost indistinguishable within the wide
range of concentrations examined.
Then, using the solid phase binding assay we more fully
characterized the interactions of 125I-talin and 125I–a-acti-
nin with the b1A and b1D cytoplasmic domain peptides
(Fig. 11, B and C). We found that the binding of 125I-talin
to the b1D peptide was severalfold higher than the bind-
ing to the b1A peptide. The apparent dissociation con-
stants of 4.2 3 1028 and 5.9 3 1029 M were calculated from
the competition binding curves for talin interactions with
the b1A and b1D cytoplasmic peptides, respectively (Fig.
11 B). Conversely, 125I–a-actinin bound more strongly to
the b1A than to the b1D cytoplasmic domain peptide (Fig.
11 C). In this case the dissociation constants were 1.2 3
1028 M for a-actinin–b1A binding and 8.8 3 1028 M for
a-actinin–b1D binding. Together, the coimmunoprecipita-
tion analyses and in vitro binding data demonstrated that
Figure 8. Digitonin insolubility
of b1A and b1D integrins is as-
cribable to cytoskeletal associa-
tion. 35S-labeled, transfected b1
integrins were immunoprecipi-
tated from digitonin-soluble (S)
and digitonin-insoluble (I) frac-
tions of either untreated (2)
or cytochalasin D–treated (1)
b1A-CHO and b1D-CHO cells.
Arrow, the mature b1 subunit;
and arrowhead, the precursor
form. Note a significant increase
in solubility of b1A and b1D in-
tegrins in 0.1% digitonin after
cytochalasin D treatment. Mo-
lecular weight markers (from top to bottom) are 200, 116, 97, 68,
and 43 kD. They are indicated to the right of the gel.
Figure 9. b1D interacts more strongly than b1A with the actin cytoskeleton and displaces the endogenous b1A and av integrins from
focal adhesions. (A–D) Localization of the transfected b1A and b1D and the endogenous b1A integrins in CHO transfectants. b1A-
CHO (A and C) and b1D-CHO (B and D) cells were double stained for human b1A (A) and hamster b1A (C) integrins, or for human
b1D (B) and hamster b1A (D) integrins. (E–H) Localization of the transfected b1A and b1D and the endogenous av integrins in GD25
transfectants. b1A-GD25 (E and G) and b1D-GD25 (F and H) cells were double stained for human b1A (E) and mouse av (G) inte-
grins, or for human b1D (F) and mouse av (H) integrins. Note colocalization of the transfected b1A with the endogenous b1A and av
integrins, whereas transfected b1D integrin displaces the endogenous b1A from focal adhesions in CHO transfectants and the endoge-
nous av integrins from focal adhesions in GD25 transfectants. (I and J) Association of the transfected b1A and b1D and the endoge-
nous b1A and av integrins with the actin cytoskeleton in CHO and GD25 transfectants. 35S-Labeled integrins were immunoprecipitated
from digitonin-soluble (S) and digitonin-insoluble (I) fractions of b1A- and b1D-transfected CHO (I) and GD25 (J) cells. (T), trans-
fected human b1A or b1D integrin; (E), endogenous hamster b1A (I) or mouse avb3/avb5 (J) integrins. Long arrows point to the ma-
ture b1 integrin subunit, short arrows mark the precursor of the b1 subunit. The large arrowhead marks the av subunit and the small ar-
rowhead marks the associated b3 and b5 subunits, not resolved under conditions of this electrophoresis. Unlike the transfected b1A,
b1D is present predominantly in the digitonin-insoluble (cytoskeletal) fraction, whereas the endogenous hamster b1A in b1D-CHO
and mouse avb3/avb5 integrins in b1D-GD25 cells are mostly digitonin-soluble. Bars, 50 mm.
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talin interacts more strongly with the cytoplasmic domain
of b1D than b1A integrin, whereas a-actinin interacts
preferentially with the b1A integrin isoform.
b1D Integrin Increases Cellular Contractility
The enhanced association of b1D integrin with the actin
cytoskeleton prompted us to examine whether the b1D in-
tegrin–cytoskeleton interaction increases contractility. When
b1A and b1D transfectants were plated on flexible silicone
rubber substrata for 1 d, b1D-transfected cells generated
prominent wrinkles within the substrata. However, b1A
transfectants were essentially unable to wrinkle these sub-
strata (Fig. 12, A–D). Interestingly, the enhancement of
contractility was not accompanied by substantially ele-
vated phosphorylation of myosin regulatory light chains in
b1D-CHO cells (Fig. 12 E). Therefore, the observed in-
crease in cellular contractility of b1D transfectants ap-
pears to be mostly because of enhancement of actin–mem-
brane attachment, and did not depend on significant
changes of myosin ATPase activity.
Discussion
In this work we have analyzed muscle b1D integrin, com-
paring its properties with those of the common b1A iso-
form. We found that the unique cytoplasmic sequence of
b1D endows this molecule with the distinctive functional
properties. b1D integrin displays an increased affinity for
both the extracellular matrix ligands and the actin cyto-
skeleton. Expression of b1D causes a marked phenotypic
conversion of both CHO and b1-deficient GD25 cells. The
b1D phenotype includes altered morphology, retarded
spreading, enhanced ligand binding, and extracellular ma-
trix assembly, as well as reduced migration and signifi-
cantly increased contractility.
Together, the increased integrin–ligand and integrin–
cytoskeleton associations mediated by the b1D isoform,
cause a significant reinforcement of the entire cytoskele-
ton–matrix link. Unlike two other b1 integrin variants b1B
and b1C, which are distributed uniformly at the cell sur-
face and are unable to interact with the actin cytoskeleton,
b1D is readily targeted to sites of cell–matrix adhesion
upon expression in nonmuscle cells. Furthermore, signifi-
cantly stronger association of b1D with the actin cytoskel-
eton can be mediated by its enhanced interaction with
Figure 10. Differential association of b1A and b1D integrins
with talin and a-actinin. (A and D) Coimmunoprecipitation of
talin and a-actinin with b1D and b1A integrins. (A) CHO trans-
fectants. Human b1A (a–d, and f) or b1D (a9–d9, and f9) integrins
were immunoprecipitated with TS2/16 mAb (a, a9, b, b9, f, and f 9)
or activation-dependent 12G10 mAb either in the absence of
Mn21 (c and c9) or in the presence of 1 mM Mn21 (d and d9). En-
dogenous hamster b1A was immunoprecipitated from b1A-CHO
(e) or b1D-CHO (e9) cells with 7E2 mAb. Immunoprecipitates
were probed for b1 integrin (a and a9), talin (b, b9, c, c9, d, d9, e,
and e9), or a-actinin (f and f9). (D) GD25 transfectants. Human
b1A (a–c) or b1D (a9–c9) integrins were immunoprecipitated
with TS2/16 mAb and immunoprecipitates were probed for b1 in-
tegrin (a and a9), talin (b and b9), or a-actinin (c and c9). Long
and short arrows mark the b1 integrin doublet (mature form and
precursor, respectively). Large arrowheads point to talin and
small arrowheads mark a-actinin. Asterisks indicate IgG heavy
chains. (B, C, E, and F) The same immunoprecipitates as in A
were probed for b1A (B) or b1D (C) integrins with the isoform-
specific antibodies. The same immunoprecipitates as in D were
blotted for b1A (E) or b1D (F).
Figure 11. Interaction of talin
and a-actinin with b1A and
b1D cytoplasmic domain pep-
tides. (A) Binding of full-
length 125I-b1A (d) and 125I-
b1D (m) cytoplasmic domain
peptides to the microtiter
wells. Shown are the average
of triplicate determinations.
(B and C) Binding of 125I-talin
(B) and 125I–a-actinin (C) to
the microtiter wells coated
with b1A (h) or b1D (j) cy-
toplasmic domain peptides in
the presence of the excess of
unlabeled talin (B) or a-acti-
nin (C). All points are the av-
erage of quadruplicate deter-
minations.
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talin and might change the organization of focal adhesions
in b1D transfectants compared with these structures in
b1A-expressing cells. However, by immunofluorescence
with a large panel of antibodies against cytoskeletal and
focal adhesion proteins, we did not observe prominent dif-
ferences in the organization of stress fibers and focal adhe-
sions between b1D and b1A transfectants. The intensities
of immunostaining for talin, vinculin, a-actinin, paxillin,
focal adhesion kinase, and phosphotyrosine at focal adhe-
sions were similar in both types of transfectants (data not
shown). Apparently, the differences in the affinities be-
tween b1A/b1D and talin/a-actinin might be insufficient
to detect preferential accumulation of these cytoskeletal
proteins at focal adhesions of b1A- and b1D-transfected
cells by immunofluorescence. Nevertheless, b1D transfec-
tants appeared to be more contractile without changes in
myosin light chain phosphorylation and displayed in-
creased resistance of focal adhesions against disassembly
by contractility inhibitors BDM and H7 (data not shown).
These observations pointed to the increased stability of fo-
cal adhesions in cells expressing b1D integrin that occurs
primarily because of enhancement of actin–membrane at-
tachment.
Simultaneously, displacement of the endogenous b1A
subunit from sites of cell–matrix adhesion by b1D gener-
ates a unique “dominant-positive phenotype” of the trans-
fected nonmuscle cells. In this situation, the b1 integrin-
mediated, cytoskeleton–matrix link is built exclusively by
the b1D integrin and lacks the b1A isoform. Displacement
of the major b1A integrin isoform from cell–matrix adhe-
sion sites appears to be a general phenomenon of b1D ex-
pression, caused by its enhanced association with the actin
cytoskeleton. This displacement is observed on various ex-
tracellular matrix substrata in a number of nonmuscle cells
(Belkin, A.M., unpublished data). Similarly, in GD25 trans-
fectants the major endogenous avb3 integrin appeared to
be displaced from the sites of cell–matrix contact. The al-
tered structure of the b1D integrin cytoplasmic domain also
leads to a conformational change in its ectodomain that in-
creases the ligand-binding affinity of b1D-containing het-
erodimers. The constitutive activation of b1D on the cell
surface, combined with its stronger interaction with the ac-
tin cytoskeleton, enhance Fn matrix assembly by b1D
transfectants (Wu et al., 1995).
Recently, Kucik et al. (1996) demonstrated that nonad-
hesive inactive state of LFA-1 integrin in lymphocytes is
maintained by the cytoskeleton. Both PMA and cytochala-
sin D were shown to stimulate lymphocyte adhesion, which
was accompanied by activation of their major b2 integrin
and its release of cytoskeletal constraints. This points to
the opposite mechanisms of cytoskeletal control of inte-
grin activation between b2 and b1 integrin subfamilies and
might reflect profoundly dissimilar physiology of nonad-
herent lymphocytes and adhesion-dependent cells, includ-
ing striated muscles.
Previously, modulation of the ligand-binding affinity of
integrin b subunits was demonstrated using either activat-
ing antibodies (Arroyo et al., 1992; Faull et al., 1993) or
point mutations in the b1 and b3 subunit cytoplasmic do-
mains (Ginsberg et al., 1992; Takada et al., 1992; O’Toole
et al., 1994, 1995; Schwartz et al., 1995). Here we present
the results showing an existence of physiological mecha-
nism reinforcing the cytoskeleton–matrix link in muscle
cells based on modulation of integrin adhesive function. This
mechanism involves a novel type of inside-out integrin sig-
naling where activation of the extracellular domain of the
integrin b subunit is controlled by alternative splicing of its
cytodomain. Since the expression of b1D and b1A iso-
forms is developmentally regulated in muscle (Belkin et al.,
1996), differentiating muscle cells can control the overall
strength of cytoskeleton–matrix attachment via alternative
splicing of the b1 integrin subunit.
The organization of focal adhesions in b1D-transfected
nonmuscle cells appears to be very similar to that found in
differentiated muscle cells. In both situations, b1D is the
only b1 isoform localized at cell–matrix adhesive struc-
tures (Belkin et al., 1996). Therefore, the enhanced cyto-
skeleton–matrix association and stabilization of focal ad-
hesions, mediated by b1D in the transfectants, might
reflect the major role for this integrin in muscle. Since
talin, a major structural component of focal adhesions, ac-
cumulates at muscle adhesions (Belkin et al., 1986; Tidball
et al., 1986), it can also serve as a key cytoskeletal element
linking b1D integrin to actin filaments in muscle. In con-
trast, we found that a-actinin, a focal adhesion component
that interacts with b1A in vitro (Otey et al., 1990), binds
b1D less strongly than b1A. This correlates with the ab-
sence of a-actinin at myotendinous junctions, the major
sites of force transmission in muscle (Tidball, 1987). Addi-
tionally, certain muscle-specific cytoskeletal proteins, in-
cluding dystrophin, may contribute to linking b1D integrin
to the subsarcolemmal cytoskeleton.
Figure 12. b1D integrin elevates cellular contractility without af-
fecting phosphorylation of myosin light chains. (A–D) Rubber
substrate contractility assay for b1A and b1D transfectants. b1A-
CHO (A), b1D-CHO (B), b1A-GD25 (C), and b1D-GD25 (D)
cells were plated for 1 d on silicone rubber substrata and photo-
graphed. (E) Myosin light chain phosphorylation in CHO trans-
fectants. Myosin was immunoprecipitated from 32P-labeled b1A-
CHO cells (a) and b1D-CHO cells (b). Immunoprecipitates were
analyzed by SDS-PAGE and autoradiography. Arrowhead points
to myosin light chains. Bar, 200 mm.
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Many existing models of focal adhesion assembly imply
that their formation proceeds from outside the cell inward,
starting from integrin clustering by their ligands on the cell
surface (Yamada and Miyamoto, 1995; Craig and Johnson,
1996). However, rho-stimulated contractility has been shown
to drive the formation of integrin-containing focal adhe-
sion complexes from inside the cell (Hotchin and Hall,
1995; Burridge and Chrzanowska-Wodnicka, 1996; Chrza-
nowska-Wodnicka and Burridge, 1996). Also, recent data
on muscle integrins in Drosophila melanogaster point to
certain ligand-independent intracellular mechanisms di-
recting localization of bps integrins (analogous to b1 inte-
grins in vertebrates) to sites of their function in embryonic
muscles (Martin-Bermudo and Brown, 1996). The altered
structure of the b1D cytoplasmic domain and the en-
hanced interaction of this integrin with the cytoskeleton
might determine its ligand-independent targeting to mus-
cle adhesive structures.
Increased Fn matrix assembly by CHO cells expressing
b1D can be driven by a combination of higher ligand-bind-
ing affinity of this integrin, reinforced actin-membrane as-
sociation and enhanced contractility of b1D transfectants.
Recently, it was shown that the appearance of new Fn ma-
trix assembly sites on the cell surface is stimulated by lyso-
phosphatidic acid, an agent that promotes contractility
(Jalink and Moolenaar, 1992; Zhang et al., 1994; Chrza-
nowska-Wodnicka and Burridge, 1996). Wu and cowork-
ers demonstrated that both integrin activation on the cell
surface and integrin–cytoskeleton interactions (postoccu-
pancy events) are essential for the assembly of a Fn matrix
(Wu et al., 1995). Our data are in agreement with these
findings. The increased Fn matrix assembly mediated by
b1D correlates well with the larger proportion of activated
integrins on the cell surface, the more stable integrin–
cytoskeleton linkage and enhanced contractility in these
transfectants. Interestingly, the observed enhancement of
Fn matrix assembly by b1D appeared to be greater than
the increase in ligand-binding affinity for b1D transfec-
tants. Even though an activation of b1A integrin with TS2/
16 mAb significantly increased Fn matrix assembly by
b1A transfectants, this still did not convert them entirely
to the b1D phenotype. These differences might reflect the
enhanced integrin–cytoskeleton association and contrac-
tility in b1D transfectants.
Finally, the increased ligand-binding, contractility, and
Fn matrix deposition contribute to the reduced cell migra-
tion of b1D transfectants. In accordance with recent find-
ings of Palecek et al. (1997), activation of the b1A ectodo-
main reduced the migration of the transfectants at substrate
concentrations and integrin expression levels used in our
experiments. Notably, integrin activation in the case of
b1A transfectants did not decrease their migration rates to
the levels characteristic for b1D-expressing cells, again
suggesting an important role for integrin–cytoskeleton in-
teractions in the generation of the b1D phenotype. To-
gether, our data demonstrate that the whole set of alter-
ations displayed by cells expressing b1D, is determined by
the distinctive structure of the b1D cytoplasmic domain.
The alternatively spliced sequence of this b1 integrin iso-
form both enhances its association with the actin cytoskel-
eton and increases receptor–ligand interaction due to con-
stitutive activation of the b1D ectodomain. Both these
factors contribute to increased Fn matrix assembly and de-
creased migration of b1D transfectants.
The changes of nonmuscle cells triggered by expression
of the b1D isoform are analogous to the transitions that
muscle cells undergo during differentiation, accompanied
by a gradual increase in the expression of this integrin
(Belkin et al., 1996). Thus, growing myotubes possess large,
extremely stable adhesions, their spreading is greatly in-
hibited and even early immature myotubes cease to mi-
grate. Although Fn matrix assembly is strongly decreased
in muscle cells, upregulation of synthesis and enhanced
deposition of certain laminin isoforms is typical for myo-
differentiation both in culture and in vivo. During myodif-
ferentiation, a dramatic increase in cellular contractility
has to be counterbalanced by the reinforcement of the cy-
toskeleton–matrix link. All these phenotypic transitions
characteristic for differentiating muscle cells generate a re-
quirement for the novel integrin, strengthening the associ-
ation between the actin cytoskeleton and the surrounding
extracellular matrix. This requirement determines the dis-
tinctive properties of b1D and defines a critical role for
this b1 integrin cytoplasmic domain in the organization
and function of adhesive structures in muscle tissues.
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